WENDY FOULKROD: Open Payments
NPI 1720073752 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,978 in 93 payments from 16 companies in 2025. Trend: 2023 $1,223 · 2024 $1,264 · 2025 $1,978
Food & beverage: $1,879Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $497 |
| Janssen Biotech, Inc. | 9 | $301 |
| Lilly USA, LLC | 9 | $239 |
| PFIZER INC. | 19 | $216 |
| Regeneron Healthcare Solutions, Inc. | 5 | $126 |
| Janssen Scientific Affairs, LLC | 2 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Aimmune Therapeutics, Inc. | 3 | $73 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $72 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
Products named: TREMFYA, RINVOQ, OMVOH, VELSIPITY, DUPIXENT, ZENPEP, XIFAXAN, MAVYRET.
Industry payments across WA — which companies pay providers there.
